Page 2 - Wakefulness Test News Today

Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1.

− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial− TAK-861 Was Found to be Generally Safe and Well-Tolerated− Results Will be Presented at an Upcoming Scientific CongressOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive topline resu...

Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase 3 trials planned for fiscal year 2024.

New positive data on TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

CSD/BSE&NSE/PR/2023-2024 October 30, 2023 To ...

Operator: Greetings. And welcome to the Alkermes Third Quarter 2023 Financial Results Conference Call. My name is Donna and I’ll be your operator for today’s call.

— Third Quarter Revenues of $380.9 Million; Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income of $47.8 Million and Non-GAAP Net Income...

Researchers from Canada found that three anti-fatigue medications can be effective at reducing daytime sleepiness. They reviewed studies of the medication on people with sleep apnea.

1. In this randomized controlled trial, an oral orexin receptor 2 (OX2R) agonist (TAK-994) was associated with improvements in wakefulness, sleepiness, and cataplexy incidence among patients with narcolepsy type 1. 2. TAK-994 was also associated with liver enzyme elevation and drug-induced hepatotoxicity. Evidence Rating Level: 1 (Excellent) Study Rundown: Narcolepsy is a rare chronic disorder

For patients with narcolepsy type 1, an orexin receptor 2 agonist, TAK-994, improves measures of sleepiness and cataplexy.